TATVA
OVERVALUEDTatva Chintan Pharma Chem Limited
Pharma · NSE
↓ 695.9% vs fair value
52W Low
₹634
+77.4% from low
52W High
₹1,610
-30.2% from high
Valuation Gauge
Current Price
₹1,124
Fair Value
₹141
Fair Value Analysis
₹141
Based on earnings growth potential for Pharma sector companies | CAUTION: ROCE declining (latest 4.5%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 5.1% (ROE 4.4%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.
Growth Valuation
100% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Weak Fundamentals
Profitability
ROE of 4.4% is below the Pharma sector benchmark of 18%
Debt & Leverage
D/E ratio of 0.1x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 78.4x is 1.9x the Pharma sector median of 42x — expensive
Cash Flow
Negative FCF of ₹-52 Cr — company is consuming more cash than it generates
Earnings Growth
5yr EPS CAGR of -60.9% — severe earnings decline
Dividend
Dividend yield of 0.1% is symbolic — low but positive
Sentiment Trend
Historical Returns
Key Financials
EPS (TTM)
₹14
P/E Ratio
78.4x
P/B Ratio
3.4x
ROE
4.4%
ROCE
1.1%
Debt / Equity
0.11x
Beta
0.34
Div Yield
0.1%
FCF (Cr)
₹-52 Cr
Revenue (Cr)
₹380 Cr
EPS Growth 5Y
-60.9%
Mkt Cap (Cr)
₹2,594 Cr
52W High
₹1,610
52W Low
₹633.6
Book Value/Share
₹326.2
Financial History
Annual P&L data not available yet.
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant